Interestingly, in comparison with sorafenib, sunitinib or regorafenib, lenvatinib inhibition of VEGFR on an HCC cell line (HepG2), assessed by the IC50 value, was reported to be 4–128 times more efficient [23]. This evidence concerns the gene KDR and hepatocellular carcinoma.